This article provides a critical appraisal of the partial cardiac denervation-postoperative atrial fibrillation (pCAD-POAF) randomized clinical trial, which investigates the effectiveness of partial cardiac denervation in reducing POAF in patients undergoing coronary artery bypass grafting (CABG). The trial demonstrated a significant reduction in POAF incidence in the intervention group compared to the control group. Despite promising results, the study has several limitations, including the exclusion of high-risk patients with advanced comorbidities and a short follow-up period, which restricts the generalizability of the findings. This appraisal examines the trial’s strengths, such as its novel approach and statistical design, while addressing areas for improvement. Future research should focus on long-term outcomes, broader patient inclusion, and the incorporation of health-related quality of life assessments.
